DOCSLIB.ORG

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008 Special Article Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic 01/14/2019 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3z4CBEZThIGzQgs/Nq8cXmasTeTnoDq64jHDuMIc/w+pngxl0ZlMZOw== by https://journals.lww.com/ccmjournal from Downloaded Downloaded Shock: 2016 1 2 from Andrew Rhodes, MB BS, MD(Res) (Co-chair) ; Laura E. Evans, MD, MSc, FCCM (Co-chair) ; https://journals.lww.com/ccmjournal Waleed Alhazzani, MD, MSc, FRCPC (methodology chair)3; Mitchell M. Levy, MD, MCCM4; Massimo Antonelli, MD5; Ricard Ferrer, MD, PhD6; Anand Kumar, MD, FCCM7; Jonathan E. Sevransky, MD, FCCM8; Charles L. Sprung, MD, JD, MCCM9; Mark E. Nunnally, MD, FCCM2; Bram Rochwerg, MD, MSc (Epi)3; Gordon D. Rubenfeld, MD (conflict of interest chair)10; by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3z4CBEZThIGzQgs/Nq8cXmasTeTnoDq64jHDuMIc/w+pngxl0ZlMZOw== Derek C. Angus, MD, MPH, MCCM11; Djillali Annane, MD12; Richard J. Beale, MD, MB BS13; Geoffrey J. Bellinghan, MRCP14; Gordon R. Bernard, MD15; Jean-Daniel Chiche, MD16; Craig Coopersmith, MD, FACS, FCCM8; Daniel P. De Backer, MD, PhD17; Craig J. French, MB BS18; Seitaro Fujishima, MD19; Herwig Gerlach, MBA, MD, PhD20; Jorge Luis Hidalgo, MD, MACP, MCCM21; Steven M. Hollenberg, MD, FCCM22; Alan E. Jones, MD23; Dilip R. Karnad, MD, FACP24; Ruth M. Kleinpell, PhD, RN-CS, FCCM25; Younsuck Koh, MD, PhD, FCCM26; Thiago Costa Lisboa, MD27; Flavia R. Machado, MD, PhD28; John J. Marini, MD29; John C. Marshall, MD, FRCSC30; John E. Mazuski, MD, PhD, FCCM31; Lauralyn A. McIntyre, MD, MSc, FRCPC32; Anthony S. McLean, MB ChB, MD, FRACP, FJFICM33; Sangeeta Mehta, MD34; Rui P. Moreno, MD, PhD35; John Myburgh, MB ChB, MD, PhD, FANZCA, FCICM, FAICD36; Paolo Navalesi, MD37; Osamu Nishida, MD, PhD38; Tiffany M. Osborn, MD, MPH, FCCM31; Anders Perner, MD39; Colleen M. Plunkett25; Marco Ranieri, MD40; Christa A. Schorr, MSN, RN, FCCM22; Maureen A. Seckel, CCRN, CNS, MSN, FCCM41; Christopher W. Seymour, MD42; Lisa Shieh, MD, PhD43; Khalid A. Shukri, MD44; Steven Q. Simpson, MD45; Mervyn Singer, MD46; B. Taylor Thompson, MD47; Sean R. Townsend, MD48; Thomas Van der Poll, MD49; Jean-Louis Vincent, MD, PhD, FCCM50; W. Joost Wiersinga, MD, PhD51, Janice L. Zimmerman, MD, MACP, MCCM52; R. Phillip Dellinger, MD, MCCM22 on 01/14/2019 *See also p. 553. 8Emory University Hospital Atlanta, GA. 1St. George’s Hospital London, England, United Kingdom. 9Hadassah Hebrew University Medical Center Jerusalem, Israel. 2New York University School of Medicine New York, NY. 10Sunnybrook Health Sciences Centre Toronto, Ontario, Canada. 3McMaster University Hamilton, Ontario, Canada. 11 University of Pittsburgh Critical Care Medicine CRISMA Laboratory 4Brown University School of Medicine Providence, RI. Pittsburgh, PA. 12 5Instituto di Anestesiologia e Rianimazione, Università Cattolica del Sacro Hospital Raymond Poincare Garches, France. Cuore, Rome, Italy. 13Saint Thomas Hospital London, England, United Kingdom. 6Vall d’Hebron University Hospital Barcelona, Spain. 14University College London Hospitals London, England, United Kingdom. 7University of Manitoba Winnipeg, Manitoba, Canada. 15Vanderbilt University Medical Center Nashville, TN. Copyright © 2017 by the Society of Critical Care Medicine and the 16Service de Reanimation Medicale Paris, France. European Society of Intensive Care Medicine 17CHIREC Hospitals Braine L’Alleud, Belgium. DOI: 10.1097/CCM.0000000000002255 18Western Hospital Victoria, Australia. 486 www.ccmjournal.org March 2017 • Volume 45 • Number 3 Copyright © 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved. Copyright © 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved. Special Article 19Keio University School of Medicine, Tokyo, Japan. Resuscitation Council, European Society of Paediatric and Neonatal Inten- 20Vivantes-Klinikum Neukölln, Berlin, Germany. sive Care, European Society for Emergency Medicine, Federación Panamer- icana e Ibérica de Medicina Crítica y Terapia Intensiva, Sociedad Peruana 21 Karl Heusner Memorial Hospital Belize Healthcare Partners Belize City, de Medicina Intensiva, Shock Society, Sociedad Argentina de Terapia Inten- Belize. siva, World Federation of Pediatric Intensive and Critical Care Societies. 22 Cooper Health System Camden, NJ. Dr. Rhodes is a past-president of the European Society of Intensive Care 23University of Mississippi Medical Center Jackson, MS. Medicine. Dr. Levy received consulting fees from ImmuneExpress. 24Jupiter Hospital Thane, India. Dr. Antonelli received funding from Pfizer, MSD, Cubist, Maquet, Drager, 25 Toray, and Baxter; he participates in ESA and SIAARTI. Dr. Kumar received Rush University Medical Center Chicago, IL. scientific consulting fees from Baxter, Isomark, and Opsonix on diagnostic 26 ASAN Medical Center University of Ulsan College of Medicine Seoul, technologies; he received grant funding from GSK in the area of influenza. South Korea. Dr. Ferrer Roca received funding from Estor, MSD, Astra-Zeneca, and Grifols 27Hospital de Clinicas de Porto Alegre Porto Alegre, Brazil. and participates in ESICM and SEMICYUC. Dr. Sevransky is an Associate 28 Editor of Critical Care Medicine. Dr. Sprung received funding from Asahi Federal University of Sao Paulo Sao Paulo, Brazil. Kasei Pharma America Corporation (consultant, Data Safety and Monitoring 29Regions Hospital St. Paul, MN. Committee) and LeukoDx Ltd. (consultant; PI, research study on biomarkers 30Saint Michael’s Hospital Toronto, Ontario, Canada. of sepsis). He participates in International Sepsis Forum (board member). Dr. 31 Angus received funding Ferring Inc (consulting fees for serving on the Trial Washington University School of Medicine St. Louis, MO. Steering Committee of a Phase 2/3 trial of selepressin for septic shock), and 32Ottawa Hospital Ottawa, Ontario, Canada. from Ibis and Genmark (both for consulting fees regarding diagnostic strate- 33 Nepean Hospital, University of Sydney Penrith, New South Wales, Australia. gies in sepsis). He is a contributing editor for JAMA, has conducted commit- 34 tee membership work for the American Thoracic Society, and has contributed Mount Sinai Hospital Toronto, Ontario, Canada. to an IOM workshop on regulatory science. Dr. Angus provided expert testi- 35UCINC, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. mony in medical malpractice cases. Dr. Beale’s institution received funding 36University of New South Wales, Sydney, New South Wales, Australia. from Roche (consulting regarding sepsis diagnostics); he received funding from Quintiles (consulting on routes to license for a potential ARDS therapy); 37Università dellla Magna Graecia Catanzaro, Italy. he participates in the UK National Institute for Clinical and Healthcare Excel- 38Fujita Health University School of Medicine, Toyoake, Aich, Japan. lence Sepsis Guideline Development Group; he has served as an expert 39Rigshospitalet Copenhagen, Denmark. witness, disclosing that he is approached from time to time regarding expert witness testimony for ICU cases, which may involve patients who have sep- 40Università Sapienza, Rome, Italy. sis and the testimony relates to generally accepted current standards of care, 41Christiana Care Health Services Newark, DE. and formal guidance, as it currently pertains within the UK. Dr. Bellingan 42University of Pittsburgh School of Medicine Pittsburgh, PA. received funding from Faron (research into interferon in lung injury) and Athersys (stem cells in lung injury). Dr. Chiche received funding for consult- 43Stanford University School of Medicine Stanford, CA. ing activities and honoraria for lectures from GE Healthcare, monitoring and 44Kaust Medical Services Thuwal, Saudi Arabia. IT solutions; he received funding from Nestlé Healthsciences (consulting 45University of Kansas Medical Center Kansas City, KS. activities and honorarium), and from Abbott diagnostics (consulting activi- ties). Dr. Coopersmith is on the fellowship committee of Surgical Infection 46 Wolfson Institute of Biomedical Research London, England, United Society. Dr. De Backer received funding from Edwards Healthcare, Frese- Kingdom. nius Kabi, and Grifols. Dr. Dellinger provided expert testimony for alleged 47Massachusetts General Hospital Boston, MA. malpractice in critical care. Dr. French participates in Australian and New 48California Pacific Medical Center San Francisco, CA. Zealand Intensive Care Society Clinical Trials Group (chair). Dr. Fujishima participates in the Japanese Association for Acute Medicine (board member, 49University of Amsterdam Amsterdam, Netherlands. Japanese Guidelines for the management of sepsis) and Japanese Respira- 50Erasmé University Hospital Brussels, Belgium. tory Society (board member, Japanese Guidelines for the management of 51University of Amsterdam, Amsterdam, Netherlands. ARDS); he received funding from Asahi Kasei Co (lecture). Dr. Hollenberg 52Houston Methodist Hospital, Houston, TX. participates in the ACC/AHA PCI and Heart Failure guidelines, CHEST edi- torial board, ACCP-SEEK, and CHEST CV Network chair. Dr. Jones partici- Corresponding author: Andrew Rhodes, St. George’s Hospital, pates in ACEP and SAEM, and has served as an expert witness on various London, United Kingdom. Email: [email protected] cases. Dr. Karnad received funding from Quintiles Cardiac Safety Services Supplemental digital content is available for this article. Direct URL cita- (consultant) and from Bharat Serum
Load more

Recommended publications
  • Copyright by Ernesto Lopez 2015
    Copyright by Ernesto Lopez 2015 The Dissertation Committee for Ernesto Lopez Certifies that this is the approved version of the following dissertation: The role of arginine vasopressin receptor 2 in microvascular hyperpermeability during severe sepsis and septic shock Committee: Perenlei Enkhbaatar, M.D., Ph.D. Supervisor or Mentor, Chair Jose M. Barral M.D., Ph.D. Donald S. Prough, M.D. Robert A. Cox, Ph.D. Jae-Woo Lee, M.D. _______________________________ David W. Niesel, PhD. Dean, Graduate School The role of arginine vasopressin receptor 2 in microvascular hyperpermeability during severe sepsis and septic shock by Ernesto Lopez, M.D. Dissertation Presented to the Faculty of the Graduate School of The University of Texas Medical Branch in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas Medical Branch 2015 Acknowledgements First I would like to gratefully thank my mentor, Dr. Enkhbaatar for his dedication and support and for giving me the opportunity to work in his lab as a graduate student. Dr. Enkhbaatar helped me to improve my scientific and professional skills with great attention. I had a true opportunity to be exposed to every aspect of the biomedical sciences. Moreover, I would like to express my gratitude to the members of my dissertation committee Dr. Prough, Dr. Cox, Dr. Barral and Dr. Lee as well as Dr. Hawkins, Dr. Herndon, Dr. Rojas and Jacob MS, for all the critiques and ideas that certainly enhanced this project. I would also like to thank to all current and past members of the translational intensive care unit (TICU) for their enormous support and professionalism in completing this project; John Salsbury, Christina Nelson, Ashley Smith, Timothy Walker, Mackenzie Gallegos, Jisoo Kim, Uma Nwikoro, Ryan Scott, Jeffrey Jinkins, Lesia Tower, Cindy Moncebaiz, Cindy Hallum, Lindsey Willis, Paul Walden, Randi Bolding, Jameisha Lee, Mengyi Ye, as well as Drs.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled
    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
    [Show full text]
  • Vasopressin, Norepinephrine, and Vasodilatory Shock After Cardiac Surgery Another “VASST” Difference?
    Vasopressin, Norepinephrine, and Vasodilatory Shock after Cardiac Surgery Another “VASST” Difference? James A. Russell, A.B., M.D. AJJAR et al.1 designed, Strengths of VANCS include H conducted, and now report the blinded randomized treat- in this issue an elegant random- ment, careful follow-up, calcula- ized double-blind controlled trial tion of the composite outcome, of vasopressin (0.01 to 0.06 U/ achieving adequate and planned Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/126/1/9/374893/20170100_0-00010.pdf by guest on 01 October 2021 min) versus norepinephrine (10 to sample size, and evaluation of 60 μg/min) post cardiac surgery vasopressin pharmacokinetics. with vasodilatory shock (Vaso- Nearly 20 yr ago, Landry et al.2–6 pressin versus Norepinephrine in discovered relative vasopressin defi- Patients with Vasoplegic Shock ciency and benefits of prophylactic After Cardiac Surgery [VANCS] (i.e., pre cardiopulmonary bypass) trial). Open-label norepinephrine and postoperative low-dose vaso- was added if there was an inad- pressin infusion in patients with equate response to blinded study vasodilatory shock after cardiac drug. Vasodilatory shock was surgery. Previous trials of vasopres- defined by hypotension requiring sin versus norepinephrine in cardiac vasopressors and a cardiac index surgery were small and underpow- greater than 2.2 l · min · m-2. The “[The use of] …vasopressin ered for mortality assessment.2–6 primary endpoint was a compos- Vasopressin stimulates arginine ite: “mortality or severe complica- infusion for treatment of vasopressin receptor 1a, arginine tions.” Patents with vasodilatory vasodilatory shock after vasopressin receptor 1b, V2, oxy- shock within 48 h post cardiopul- tocin, and purinergic receptors monary bypass weaning were eli- cardiac surgery may causing vasoconstriction (V1a), gible.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Distribution and Relative Expression of Vasoactive Receptors on Arteries Xinhao Liu1,3, Dan Luo1,3, Jie Zhang2 & Lei Du1*
    www.nature.com/scientificreports OPEN Distribution and relative expression of vasoactive receptors on arteries Xinhao Liu1,3, Dan Luo1,3, Jie Zhang2 & Lei Du1* Arterial tone is regulated by multiple ligand-receptor interactions, and its dysregulation is involved in ischemic conditions such as acute coronary spasm or syndrome. Understanding the distribution of vasoactive receptors on diferent arteries may help guide the development of tissue-specifc vasoactive treatments against arterial dysfunction. Tissues were harvested from coronary, mesenteric, pulmonary, renal and peripheral human artery (n = 6 samples of each) and examined using a human antibody array to determine the expression of 29 vasoactive receptors and 3 endothelin ligands. Across all types of arteries, outer diameter ranged from 2.24 ± 0.63 to 3.65 ± 0.40 mm, and AVPR1A was the most abundant receptor. The expression level of AVPR1A in pulmonary artery was similar to that in renal artery, 2.2 times that in mesenteric artery, 1.9 times that in peripheral artery, and 2.2 times that in coronary artery. Endothelin-1 was expressed at signifcantly higher levels in pulmonary artery than peripheral artery (8.8 times), mesenteric artery (5.3 times), renal artery (7.9 times), and coronary artery (2.4 times). Expression of ADRA2B was signifcantly higher in coronary artery than peripheral artery. Immunohistochemistry revealed abundant ADRA2B in coronary artery, especially vessels with diameters below 50 μm, but not in myocardium. ADRA2C, in contrast, was expressed in both myocardium and blood vessels. The high expression of ADRA2B in coronary artery but not myocardium highlights the need to further characterize its function.
    [Show full text]
  • Terlipressin Or Norepinephrine in Septic Shock: Do We Have the Answer?
    1273 Editorial Commentary Terlipressin or norepinephrine in septic shock: do we have the answer? Mark D. Williams1, James A. Russell2 1Department of Medicine, Indiana University School of Medicine, Indiana University Health Methodist Hospital, Indianapolis, IN, USA; 2Centre for Heart Lung Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada Correspondence to: Dr. James A. Russell, AB, MD. Centre for Heart Lung Innovation, St. Paul’s Hospital, 1081 Burrard St., Vancouver, BC V6Z 1Y6, Canada. Email: [email protected]. Provenance: This is an invited article commissioned by the Section Editor Xue-Zhong Xing [National Cancer Center (NCC)/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China]. Comment on: Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med 2018;44:1816-25. Submitted Feb 02, 2019. Accepted for publication Feb 18, 2019. doi: 10.21037/jtd.2019.05.07 View this article at: http://dx.doi.org/10.21037/jtd.2019.05.07 Despite increased attention on prevention and early recent studies have reported that the efficacy of vasopressin aggressive treatment with antibiotics and smart fluid in clinical practice may be disappointing (6). Sacha and resuscitation, there remains high morbidity and mortality colleagues (6) reported a 45% response rate to vasopressin from septic shock globally (1). Frequently septic patients (defined by decreased catecholamine dose and stable blood develop persistent distributive shock that often requires pressure by six hours after initiation of vasopressin) and that vasopressor infusion to restore adequate mean arterial patients treated after 12 hours and those with a high lactate pressure (MAP) in order to provide adequate perfusion had a lower response to vasopressin.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub
    US 20160354315A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub. Date: Dec. 8, 2016 (54) DOSAGE FORMS AND USE THEREOF Publication Classification (71) Applicant: Triastek, Inc., Nanjing (CN) (51) Int. Cl. A69/20 (2006.01) (72) Inventor: Xiaoling Li, Dublin, CA (US) A6IR 9/24 (2006.01) A63L/92 (2006.01) (52) U.S. Cl. (21) Appl. No.: 15/173,596 CPC ........... A61K 9/2031 (2013.01); A61K 9/2027 (2013.01); A61K 31/192 (2013.01); A61 K 9/209 (2013.01) (22) Filed: Jun. 3, 2016 (57) ABSTRACT The present disclosure provides a stable solid pharmaceuti Related U.S. Application Data cal dosage form for oral administration. The dosage form includes a Substrate that forms at least one compartment and (60) Provisional application No. 62/170,645, filed on Jun. a drug content loaded into the compartment. The dosage 3, 2015, provisional application No. 62/313,092, filed form is so designed that the active pharmaceutical ingredient on Mar. 24, 2016. of the drug content is released in a controlled manner. Patent Application Publication Dec. 8, 2016 Sheet 1 of 20 US 2016/0354315 A1 FG. A F.G. B. Peak carcetitration, tax ise F.G. C Patent Application Publication Dec. 8, 2016 Sheet 2 of 20 US 2016/0354315 A1 F.G. 2B Patent Application Publication Dec. 8, 2016 Sheet 3 of 20 US 2016/0354315 A1 F.G. 3 Patent Application Publication Dec. 8, 2016 Sheet 4 of 20 US 2016/0354315 A1 Patent Application Publication Dec.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 1 a Global Perspective on Vasoactive Agents in Shock
    Manuscript Click here to download Manuscript A global perspective on vasoactive agents in shock R2.docx Click here to view linked References 1 A global perspective on vasoactive agents in shock Authors*: Djillali Annane, Lamia Ouanes-Besbes, 1 2 2 Daniel de Backer, Bin DU, Anthony C Gordon, Glenn Hernández, Keith M. Olsen, Tiffany M. Osborn, Sandra 3 4 3 Peake, James A. Russell, Sergio Zanotti Cavazzoni 5 6 4 *All authors have equally contributed to this manuscript 7 8 5 Address: 9 10 6 Djillali Annane, MD, PhD 11 12 7 General ICU, Raymond Poincaré hospital (APHP), School of medicine Simone Veil, U1173 Laboratory of 13 14 8 Infection& Inflammation (University of Versailles SQY- University Paris Saclay / INSERM) – CRICS- 15 16 9 TRIGERSEP network (F-CRIN), 104 boulevard Raymond Poincaré, 92380 Garches, France 17 18 10 Lamia Ouanes-Besbes, MD 19 20 11 Intensive Care Unit, CHU F. Bourguiba ; Monastir, Tunisia 21 22 12 Daniel de Backer, MD,PhD 23 24 13 Department of intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Brussels, Belgium 25 26 14 Bin DU, MD 27 28 15 Medical ICU, Peking Union Medical College Hospital; 1 Shuai Fu Yuan, Beijing 100730; China 29 30 16 Anthony C Gordon, MD, FRCA, FFICM 31 32 17 Section of Anaesthetics, Pain Medicine & Intensive Care, Imperial College London, UK 33 34 18 Glenn Hernández, MD, PhD 35 36 Departamento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Chile 37 19 38 39 20 Keith M. Olsen, PharmD, FCCP, FCCM 40 41 21 UAMS College of Pharmacy.
    [Show full text]
  • Supplementary Data
    Supplementary data Table S1. Results of the docking of DrugBank compounds onto GRP78 (NBD) (only molecules with lower docking scores than control ATP are presented). Molecule name Final docking score S (kcal/mol) Imatinib -9.26206 FK-614 -8.9803 Selonsertib -8.85865 Sorafenib -8.841712 CID 5288250 -8.6442 Pemetrexed -8.6247129 4SC-203 -8.61179 Zafirlukast -8.59865 (2S)-2-[[4-[2-[(6S)-2-Amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin- -8.58657 6-yl]ethyl]benzoyl]amino]pentanedioic acid Icariin -8.46474 Raltegravir -8.44994 4-[(5-{[4-(3-Chlorophenyl)-3-oxopiperazin-1-YL]methyl}-1H-imidazol-1- -8.44899 YL)methyl]benzonitrile Dacomitinib -8.4483 [(1S)-1-Cyclohexyloxycarbonyloxyethyl] 2-ethoxy-3-[[4-[2-(2H-tetrazol-5- -8.43484 yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate Darexaban -8.4267 Tenofovir disoproxil -8.4124937 Neratinib -8.39573 Ponatinib -8.38035 6-(3-(Dimethylcarbamoyl)phenylsulfonyl)-4-(3-methoxyphenylamino)-8- -8.32773 methylquinoline-3-carboxamide 2'-Deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate) -8.31957 3-(5-{[4-(Aminomethyl)piperidin-1-Yl]methyl}-1h-Indol-2-Yl)quinolin-2(1h)-One -8.30333 (2R)-N-[2-[4-[5-[4-[(4-Acetamidophenyl)methoxy]-2,3-dichlorophenyl]-2- -8.2941 methylpyrazol-3-yl]piperidin-1-yl]-2-oxoethyl]-2-(diaminomethylideneamino)- 4-methylpentanamide Butafenacil -8.29337 Nilotinib -8.28767 Gedatolisib -8.27715 N-(Sulfanylacetyl)tyrosylprolylmethioninamide -8.27166 Leucovorin -8.2563314 Asp3026 -8.24956 Methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[[4-[(2-methylquinolin-4- -8.2435 yl)methoxy]phenyl]methyl]cyclopropane-1-carboxylate
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]